Athira Pharma Inc.

05/09/2022 | Press release | Distributed by Public on 05/09/2022 05:06

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease